Parkinson's Disease ER Stress/UPR Modulator Companies

Overview

Overview

This category page covers biotechnology and pharmaceutical companies developing [ER stress](/mechanisms/er-stress-upr-parkinsons) and [unfolded protein response](/entities/upr) (UPR) modulators specifically for Parkinson's disease. The [ER stress pathway](/mechanisms/er-stress-upr-parkinsons) is a central pathological mechanism in PD, where protein misfolding, calcium dysregulation, and mitochondrial dysfunction converge to trigger chronic ER stress and ultimately dopaminergic neuron death. [@wang2020]

Targeting ER stress and the UPR offers disease-modifying potential by addressing proteostasis failure—a root cause of neurodegeneration rather than just symptomatic relief.

Key Therapeutic Rationale

The ER stress/UPR pathway is particularly relevant for Parkinson's disease because: [@hashimoto2021]

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| Chemical Chaperones | Enhance ER folding capacity (TUDCA, PBA) | Amylyx |
| PERK/eIF2α Modulators | Inhibit pro-apoptotic signaling | Research-stage |
| IRE1 RNASE Modulators | Reduce chronic RNase activity | Research-stage |
| ATF6 Activators | Promote adaptive chaperone expression | Research-stage |
| Anti-apoptotic Agents | Block CHOP-mediated apoptosis | Research-stage |

ER Stress Modulator Companies for PD

Amylyx Pharmaceuticals — Relyvrio (AMX0035)

Amylyx Pharmaceuticals (NASDAQ: AMLX) is the only company with an approved ER stress-modulating drug relevant to Parkinson's disease.

• Lead Candidate: [Relyvrio](/companies/amylyx) (AMX0035), a fixed-dose combination of sodium phenylbutyrate and taurursodiol (TUDCA)
• Mechanism:
• Sodium phenylbutyrate: Chemical chaperone that reduces ER stress by enhancing protein folding capacity
• Taurursodiol (TUDCA): Bile acid derivative that inhibits ER-mediated apoptosis by stabilizing mitochondrial membranes
• Primary Indication: Amyotrophic lateral sclerosis (ALS) — Approved in US (2022) and Canada
• PD Relevance: Both components directly target ER stress pathways. While not specifically in PD trials, the mechanism is highly relevant to PD pathogenesis
• Clinical Development: AMX0035 showed significant benefit in ALS Phase 2 CENTAUR trial; Phase 3 PHOENIX trial completed 2024
• Pipeline: Planning Phase 2 trial in Progressive Supranuclear Palsy (PSP)

Cyclo Therapeutics — CTX-2103 (Cyclobenzaprine Derivatives)

Cyclo Therapeutics is developing cyclobenzaprine derivatives targeting ER stress in neurodegenerative diseases.

• Lead Candidate: CTX-2103 and related compounds
• Mechanism: Cyclobenzaprine is a tricyclic antidepressant that also induces Hsp70 and reduces ER stress
• Target: ER stress reduction through Hsp70 induction and protein folding enhancement
• Indication: Alzheimer's disease and potentially Parkinson's disease
• Status: Preclinical/Research stage
• PD Relevance: Hsp70 induction can reduce misfolded protein burden in dopaminergic neurons

Companies with ER Stress Programs in Development

| Company | Program | Mechanism | PD Status |
|---------|---------|-----------|-----------|
| Denali Therapeutics | DNL343 | LRRK2 inhibitor with ER stress modulation | Phase 1 |
| Prevail Therapeutics | PR001 | AAV-GBA1 (reduces ER stress from GCase deficiency) | Phase 1/2 |
| Vanqua Bio | VQVN | LRRK2 inhibitor | Phase 2 |
| Gain Therapeutics | GT-02287 | GCase activator | Preclinical |

Denali Therapeutics — DNL343

Denali Therapeutics has an ER stress modulation component to their LRRK2 inhibitor program.

• Lead Candidate: DNL343
• Mechanism: LRRK2 kinase inhibitor with additional ER stress reduction activity through XBP1 activation
• Indication: Parkinson's disease — Phase 1
• Rationale: [LRRK2](/genes/lrrk2) mutations cause increased ER stress; LRRK2 inhibition reduces UPR activation
• Status: Phase 1 ongoing

Prevail Therapeutics — PR001 (AAV-GBA1)

Prevail Therapeutics (acquired by Eli Lilly) is developing gene therapy for GBA-associated PD.

• Lead Candidate: PR001
• Mechanism: AAV-mediated delivery of functional GBA1 gene to restore glucocerebrosidase activity
• PD Rationale: [GBA](/genes/gba1) mutations cause ER stress through multiple mechanisms—impaired protein folding, lysosomal dysfunction, and alpha-synuclein accumulation
• Indication: Parkinson's disease with GBA1 mutations — Phase 1/2
• Status: Clinical trials ongoing

Related Pages

Mechanism Pages

• [ER Stress and UPR in Parkinson's Disease](/mechanisms/er-stress-upr-parkinsons)
• [LRRK2 Pathway in Parkinson's Disease](/mechanisms/lrrk2-pathway-parkinsons)
• [GBA Pathway in Parkinson's Disease](/mechanisms/gba-pathway-parkinsons)

Therapeutic Pages

• [ER Stress and UPR Modulator Therapy](/therapeutics/er-stress-upr-modulator-therapy)
• [TUDCA and UDCA for Neurodegeneration](/therapeutics/tudca-udca-neurodegeneration)
• [Relyvrio (AMX0035) for ALS](/therapeutics/relyvrio-als)

Company Pages

• [Amylyx Pharmaceuticals](/companies/amylyx)
• [Cyclo Therapeutics](/companies/cyclo-therapeutics)
• [Denali Therapeutics](/companies/denali-therapeutics)
• [Prevail Therapeutics](/companies/prevail-therapeutics)

Pipeline Pages

• [PD Pipeline](/companies/pd-pipeline)
• [PD Lysosomal/Autophagy Companies](/companies/pd-lysosomal-autophagy-companies)